Silicon Valley Bank’s Failure Rattles Investors In Biopharma Sector

Investment bank analysts, VC funds and biopharma companies all sought to calm investors’ nerves as a go-to financial institution for tech and biotech collapsed.

Investors were rattled as Silicon Valley Bank, which long served biotech as well as technology companies, failed on 10 March • Source: Shutterstock

The failure of Silicon Valley Bank, the largest bank failure since Washington Mutual collapsed in 2008, has raised concerns among investors about potential contagion, but also about the significant exposure of the biotech sector to a bank that had long been a go-to financial institution for tech and biopharma companies as well as venture capital firms.

On 10 March, the Federal Deposit Insurance Corporation took over SVB after financial regulators in California closed it down and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.